Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.047
AS - Asia 8.036
EU - Europa 7.750
SA - Sud America 1.171
AF - Africa 204
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 7
Totale 28.230
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.405
SG - Singapore 3.004
SE - Svezia 2.359
IT - Italia 1.849
CN - Cina 1.366
HK - Hong Kong 1.196
VN - Vietnam 1.074
RU - Federazione Russa 925
BR - Brasile 864
DE - Germania 784
CA - Canada 527
IE - Irlanda 518
FR - Francia 253
GB - Regno Unito 243
BD - Bangladesh 236
IN - India 233
ID - Indonesia 187
UA - Ucraina 154
FI - Finlandia 142
AT - Austria 121
AR - Argentina 117
KR - Corea 117
IQ - Iraq 88
TR - Turchia 88
NL - Olanda 87
ES - Italia 77
PK - Pakistan 73
JP - Giappone 65
MX - Messico 62
ZA - Sudafrica 61
PH - Filippine 57
DK - Danimarca 54
SA - Arabia Saudita 47
EC - Ecuador 42
CH - Svizzera 41
CO - Colombia 41
PL - Polonia 37
VE - Venezuela 33
UZ - Uzbekistan 31
CL - Cile 28
JO - Giordania 26
KE - Kenya 26
MA - Marocco 26
TN - Tunisia 19
JM - Giamaica 17
LT - Lituania 17
PS - Palestinian Territory 17
BE - Belgio 16
PY - Paraguay 16
EG - Egitto 15
AE - Emirati Arabi Uniti 13
AL - Albania 13
RO - Romania 13
AU - Australia 12
MY - Malesia 12
TH - Thailandia 12
UY - Uruguay 12
DZ - Algeria 11
ET - Etiopia 10
KZ - Kazakistan 10
AZ - Azerbaigian 9
BO - Bolivia 9
CR - Costa Rica 9
IR - Iran 9
NP - Nepal 9
CZ - Repubblica Ceca 8
IL - Israele 8
LB - Libano 8
OM - Oman 8
PE - Perù 8
TW - Taiwan 7
CI - Costa d'Avorio 6
HN - Honduras 6
AM - Armenia 5
NG - Nigeria 5
PT - Portogallo 5
SC - Seychelles 5
BG - Bulgaria 4
BY - Bielorussia 4
EU - Europa 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
BH - Bahrain 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GR - Grecia 3
GT - Guatemala 3
LY - Libia 3
MN - Mongolia 3
MT - Malta 3
MU - Mauritius 3
PA - Panama 3
SN - Senegal 3
SY - Repubblica araba siriana 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
DM - Dominica 2
HU - Ungheria 2
KG - Kirghizistan 2
Totale 28.190
Salva come PNG Salva come JPEG
Città #
Stockholm 1.887
Singapore 1.766
Ann Arbor 1.734
Hong Kong 1.165
Ashburn 932
San Jose 776
Milan 511
Frankfurt am Main 509
Fairfield 506
Dublin 505
Toronto 405
Chandler 367
Wilmington 353
New York 348
Woodbridge 305
Ho Chi Minh City 290
Hanoi 283
Houston 261
Santa Clara 261
Chicago 253
Dallas 242
Los Angeles 221
Hefei 209
Seattle 207
The Dalles 187
Cambridge 184
Beijing 174
Princeton 160
Jakarta 153
Lauterbourg 136
Council Bluffs 129
Jacksonville 114
Seoul 105
Dearborn 86
Moscow 84
Helsinki 79
Vienna 78
Buffalo 77
Boardman 76
Lawrence 74
Altamura 72
São Paulo 71
Shanghai 69
London 61
Rome 60
Munich 56
San Diego 55
Haiphong 52
Tokyo 52
Nuremberg 49
Guangzhou 46
Montreal 43
Orem 40
Da Nang 39
Rio de Janeiro 39
Baghdad 37
Zurich 37
Nanjing 36
Andover 33
Desio 33
Lappeenranta 31
Atlanta 30
Brooklyn 30
Mumbai 29
Salt Lake City 29
Denver 28
Dong Ket 27
Warsaw 27
Phoenix 26
Tashkent 26
Chennai 25
Hải Dương 24
Monza 24
Amman 23
Johannesburg 22
Kent 22
Lissone 22
Pune 22
Changsha 21
Falls Church 21
Lahore 21
Nairobi 21
Amsterdam 20
Dhaka 20
Poplar 20
Columbus 19
Paris 19
Belo Horizonte 18
Florence 18
Jeddah 18
Naples 18
Riyadh 18
Tampa 18
Tianjin 18
Ha Long 17
Kocaeli 17
Ottawa 17
San Francisco 17
Turku 17
Zhengzhou 17
Totale 18.049
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.957
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 565
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 451
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 443
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 430
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 395
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 394
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 389
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 374
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 369
A second update on mapping the human genetic architecture of COVID-19 365
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 354
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 354
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 353
Mapping the human genetic architecture of COVID-19 345
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 337
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 326
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 312
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 310
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 309
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 302
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 294
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 293
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 292
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 291
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 291
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 287
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 271
A multidisciplinary approach to screen the post-COVID-19 conditions 266
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 265
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 258
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 256
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 252
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 248
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 247
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 245
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 243
When progressive dysphagia could be related to an “old friend” – a case report 241
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 238
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 237
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 236
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 224
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 219
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 218
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 215
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 214
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 214
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 212
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 210
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 207
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 203
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 200
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial 196
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 195
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 194
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 191
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 190
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 189
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 188
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 185
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 183
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 181
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 181
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 179
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 179
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 178
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 178
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 177
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 176
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 174
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 173
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 173
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 172
Metronomic chemotherapy 171
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 168
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 166
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 165
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 164
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 163
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 159
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 157
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 157
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 155
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 152
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study 151
Adjuvant systemic treatment of early breast cancer: the NORA study 151
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 150
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 148
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 146
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 144
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 142
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 141
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 139
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 137
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 136
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 135
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 130
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial 127
Gene expression profiling in breast cancer: a clinical perspective 125
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 124
Totale 24.856
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.889
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.889
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021191 0 0 0 0 0 0 0 0 0 0 0 191
2021/20221.198 126 121 150 87 49 90 62 89 58 75 85 206
2022/20232.106 252 550 162 154 121 268 135 140 100 62 87 75
2023/20241.945 89 75 67 93 255 397 354 57 171 56 65 266
2024/20255.336 260 748 412 263 373 265 308 171 561 765 387 823
2025/202613.626 1.320 845 839 1.182 1.282 574 1.748 651 1.082 2.882 799 422
Totale 29.003